Omega Diagnostics Group Plc (LON:ODX)‘s stock had its “corporate” rating reissued by research analysts at FinnCap in a note issued to investors on Monday. They presently have a GBX 28 ($0.34) target price on the stock. FinnCap’s price objective suggests a potential upside of 44.52% from the company’s current price.

Omega Diagnostics Group Plc (LON:ODX) traded up 6.164% during mid-day trading on Monday, reaching GBX 19.375. The company’s stock had a trading volume of 229,961 shares. The stock’s market cap is GBX 21.07 million. Omega Diagnostics Group Plc has a 52-week low of GBX 13.50 and a 52-week high of GBX 21.00. The company has a 50 day moving average of GBX 16.93 and a 200-day moving average of GBX 16.79.

Omega Diagnostics Group Plc Company Profile

Omega Diagnostics Group PLC, based in the United Kingdom, is a holding company. The Company, along with its subsidiaries is engaged in manufacture, development and distribution of medical diagnostics products. The Company operates in three segments: Allergy and Autoimmune, Food Intolerance and Infectious Disease and Other.

Receive News & Ratings for Omega Diagnostics Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group Plc and related companies with's FREE daily email newsletter.